Recombinant Vaccines Market By Indication (Human Papillomavirus, Meningococcal, Others), By End User (Pediatric, Adults), By Distribution Channel (Hospitals, Vaccination Centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Recombinant Vaccines Market

Recombinant vaccines rely on the capacity of one or multiple defined antigens to induce immunity against the pathogen, when administered in the presence of adjuvants or when expressed by plasmids or harmless bacterial/viral vectors. Recombinant protein vaccines permit the avoidance of several potential concerns raised by vaccines based on purified macromolecules, such as the risk of co-purification of undesired contaminants or reversal of the toxoids to their toxigenic forms, if considering diphtheria or tetanus toxoid vaccines, for example. Another fundamental issue overcome by this technology is the complexity involved in obtaining sufficient quantities of purified antigenic components. However, one of the main challenges in the development of these new strategies of immunization consists of designing vaccines that elicit the appropriate kind of immune response to confer immunity mainly to intracellular pathogens and especially to those that establish chronic, often lifelong infections. For this, the knowledge of the biology of highly conserved antigens involved in pathogenesis and of the immune mechanisms that should be elicited for protection must be obtained to rationally design vaccine strategies that can overcome the low protective immunity naturally generated by infection. There are a variety of expression systems for antigenic protein components, such as bacteria, yeast, mammalian cells and insect cells, in which the DNA encoding the antigenic determinant can be inserted and expressed. However, several factors must be taken into account before selecting the system for antigen expression. Most of the vaccines under investigation are based on highly purified recombinant proteins or subunits of pathogens. The classical example of recombinant protein vaccines currently in use in humans is the vaccine against hepatitis B. Hepatitis B virus (HBV) infection is a chronic liver disease occurring worldwide. HBV presents a marked tropism for human liver cells, partially due to a specific receptor that is expressed on the surface of infected cells.

The key drivers for the recombinant vaccines market size are increase in research and development activities for recombinant vaccines, rise in the prevalence of infectious diseases and increase in rates of vaccinations globally. Moreover, increasing incidence of zoonotic diseases, emerging technologies for developing vaccines and rise in the number of product approvals also helps in the growth of the recombinant vaccines market size. For instance, in June 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, prolong period for introduction of new vaccines is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the growth of the recombinant vaccines market share.

The COVID-19 pandemic had a positive impact on the recombinant vaccines industry owing to the increase in the research and development activities for development of effective vaccines. In addition, the increase in the advantages of vaccines also helped in the growth of the vaccines.

On the basis of indication, the market is classified into human papillomavirus, meningococcal and others. The human papillomavirus segment is projected to exhibit the fastest market growth during the forecast period, owing to increase in the prevalence of chronic diseases among the population, increase in the healthcare expenditure and increase in the adoption of recombinant vaccines technology.

On the basis of end user, the market is classified into pediatric and adult. The pediatric segment is anticipated to grow at the highest rate, owing to upsurge in number of patients of infectious diseases and increase in the number of vaccinations of the adult population globally and increase in the number of research and development activities for the recombinant vaccines used in the prevention of various diseases. Moreover, the rise in the prevalence of chronic diseases like hepatitis also helps in the growth of pediatric segment in the recombinant vaccines market share.

On the basis of distribution channel, the market is classified into hospitals and vaccination centers. The hospitals segment is further subsegment on the basis of type into private and public. The hospitals segment is anticipated to grow at the highest rate, owing to increase in the number of biotechnology companies that mainly focus on the development of recombinant vaccines, increase the research activities of vaccines development. Moreover, the rise in number of public hospitals with sufficient number of medical staff also contributes in the growth of the market.

On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). In 2021, North America was the dominant region and is expected to remain dominant throughout the recombinant vaccines market forecast period, owing to high prevalence rate of chronic disease, increase in the number market players and surge in the vaccination rates in the region. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, owing to the presence of high populace countries such as India and China, which in turn increases the prevalence rate of infectious diseases, geriatric population, and the increasing number of product launch and other recombinant vaccines market trends adopted by the market players.

The key market players operating in this market include, AstraZeneca Plc., Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd.

KEY FINDINGS OF STUDY

By indication, the human papillomavirus segment accounted for major share of the recombinant vaccines industry in 2021.

By end user, the pediatric segment is anticipated to grow with the highest CAGR throughout the forecast period.

By distribution channel, the hospitals segment is anticipated to grow with the highest CAGR throughout the recombinant vaccines market analysis period.

By region, North America occupied major share of the recombinant vaccines market in 2021.

Overview

The global recombinant vaccines market was valued at $8,080.37 million in 2021, and is projected to reach $24,698.79 million by 2031, registering a CAGR of 11.4% from 2022 to 2031.

A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune response into bacterial or mammalian cells, expressing the antigen in these cells and then purifying it from them. It is expressed as DNA, proteins and live vaccines. The DNA version is cheaper to make and is thermostable, which does not require the “cold chain” for transportation and preservation. A large number of studies have been done on development of DNA vaccines. However, a few DNA vaccines have succeeded in becoming DNA vaccines for human use. The live recombinant vaccines are made of a live viral or bacterial vector that was engineered to express a variety of exogenous antigens in the cytoplasm of target cells, in this case HIV-1 or genes.

The growth of the recombinant vaccines market is driven by increase in research and development activities for recombinant vaccines, rise in the prevalence of infectious diseases and increase in rates of vaccinations globally. Moreover, increasing incidence of zoonotic diseases, emerging technologies for developing vaccines and rise in the number of product approvals also helps in the growth of the market. For instance, in June 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, prolong period for introduction of new vaccines is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

The global recombinant vaccines market is segmented based on indication, end user, distribution channel and region. On the basis of indication, the market is bifurcated into human papillomavirus, meningococcal and others. On the basis of end user, the market is classified into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. The hospitals segment is further subsegment on the basis of type into private and public. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include, AstraZeneca Plc., Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the recombinant vaccines market analysis from 2021 to 2031 to identify the prevailing recombinant vaccines market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the recombinant vaccines market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global recombinant vaccines market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Pfizer Inc

Scope of Recombinant Vaccines Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Human Papillomavirus

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Meningococcal

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Others

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Pediatric

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Adults

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospitals

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.2.4 Hospitals Recombinant Vaccines Market by Type

6.2.4.1 Private Market size and forecast, by region

6.2.4.2 Public Market size and forecast, by region

6.3 Vaccination Centers

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Indication

7.2.3 North America Market size and forecast, by End User

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.4.1 North America Hospitals Recombinant Vaccines Market by Type

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Indication

7.2.5.1.2 Market size and forecast, by End User

7.2.5.1.3 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Indication

7.2.5.2.2 Market size and forecast, by End User

7.2.5.2.3 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Indication

7.2.5.3.2 Market size and forecast, by End User

7.2.5.3.3 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Indication

7.3.3 Europe Market size and forecast, by End User

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.4.1 Europe Hospitals Recombinant Vaccines Market by Type

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Indication

7.3.5.1.2 Market size and forecast, by End User

7.3.5.1.3 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Indication

7.3.5.2.2 Market size and forecast, by End User

7.3.5.2.3 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Indication

7.3.5.3.2 Market size and forecast, by End User

7.3.5.3.3 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Indication

7.3.5.4.2 Market size and forecast, by End User

7.3.5.4.3 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Indication

7.3.5.5.2 Market size and forecast, by End User

7.3.5.5.3 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Indication

7.3.5.6.2 Market size and forecast, by End User

7.3.5.6.3 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Indication

7.4.3 Asia-Pacific Market size and forecast, by End User

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.4.1 Asia-Pacific Hospitals Recombinant Vaccines Market by Type

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Indication

7.4.5.1.2 Market size and forecast, by End User

7.4.5.1.3 Market size and forecast, by Distribution Channel

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Indication

7.4.5.2.2 Market size and forecast, by End User

7.4.5.2.3 Market size and forecast, by Distribution Channel

7.4.5.3 Australia

7.4.5.3.1 Market size and forecast, by Indication

7.4.5.3.2 Market size and forecast, by End User

7.4.5.3.3 Market size and forecast, by Distribution Channel

7.4.5.4 India

7.4.5.4.1 Market size and forecast, by Indication

7.4.5.4.2 Market size and forecast, by End User

7.4.5.4.3 Market size and forecast, by Distribution Channel

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Indication

7.4.5.5.2 Market size and forecast, by End User

7.4.5.5.3 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Indication

7.4.5.6.2 Market size and forecast, by End User

7.4.5.6.3 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Indication

7.5.3 LAMEA Market size and forecast, by End User

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.4.1 LAMEA Hospitals Recombinant Vaccines Market by Type

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Indication

7.5.5.1.2 Market size and forecast, by End User

7.5.5.1.3 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Indication

7.5.5.2.2 Market size and forecast, by End User

7.5.5.2.3 Market size and forecast, by Distribution Channel

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Indication

7.5.5.3.2 Market size and forecast, by End User

7.5.5.3.3 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Indication

7.5.5.4.2 Market size and forecast, by End User

7.5.5.4.3 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Pfizer Inc.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 2. RECOMBINANT VACCINES MARKET, FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2021-2031 ($MILLION)

TABLE 3. RECOMBINANT VACCINES MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. RECOMBINANT VACCINES MARKET, FOR MENINGOCOCCAL, BY REGION, 2021-2031 ($MILLION)

TABLE 5. RECOMBINANT VACCINES MARKET FOR MENINGOCOCCAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. RECOMBINANT VACCINES MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 7. RECOMBINANT VACCINES MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. GLOBAL RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 9. RECOMBINANT VACCINES MARKET, FOR PEDIATRIC, BY REGION, 2021-2031 ($MILLION)

TABLE 10. RECOMBINANT VACCINES MARKET FOR PEDIATRIC, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 11. RECOMBINANT VACCINES MARKET, FOR ADULTS, BY REGION, 2021-2031 ($MILLION)

TABLE 12. RECOMBINANT VACCINES MARKET FOR ADULTS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. GLOBAL RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 14. RECOMBINANT VACCINES MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)

TABLE 15. RECOMBINANT VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 16. GLOBAL HOSPITALS RECOMBINANT VACCINES MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 17. RECOMBINANT VACCINES MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION)

TABLE 18. RECOMBINANT VACCINES MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION)

TABLE 19. RECOMBINANT VACCINES MARKET, FOR VACCINATION CENTERS, BY REGION, 2021-2031 ($MILLION)

TABLE 20. RECOMBINANT VACCINES MARKET FOR VACCINATION CENTERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 21. RECOMBINANT VACCINES MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 22. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 23. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 24. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 25. NORTH AMERICA HOSPITALS RECOMBINANT VACCINES MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 26. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 27. U.S. RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 28. U.S. RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 29. U.S. RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 30. CANADA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 31. CANADA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 32. CANADA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 33. MEXICO RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 34. MEXICO RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 35. MEXICO RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 36. EUROPE RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 37. EUROPE RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 38. EUROPE RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 39. EUROPE HOSPITALS RECOMBINANT VACCINES MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 40. EUROPE RECOMBINANT VACCINES MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 41. GERMANY RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 42. GERMANY RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 43. GERMANY RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 44. FRANCE RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 45. FRANCE RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 46. FRANCE RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 47. UK RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 48. UK RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 49. UK RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 50. ITALY RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 51. ITALY RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 52. ITALY RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 53. SPAIN RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 54. SPAIN RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 55. SPAIN RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 56. REST OF EUROPE RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 57. REST OF EUROPE RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 58. REST OF EUROPE RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 59. ASIA-PACIFIC RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 60. ASIA-PACIFIC RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 61. ASIA-PACIFIC RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 62. ASIA-PACIFIC HOSPITALS RECOMBINANT VACCINES MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 63. ASIA-PACIFIC RECOMBINANT VACCINES MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 64. JAPAN RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 65. JAPAN RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 66. JAPAN RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 67. CHINA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 68. CHINA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 69. CHINA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 70. AUSTRALIA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 71. AUSTRALIA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 72. AUSTRALIA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 73. INDIA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 74. INDIA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 75. INDIA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 76. SOUTH KOREA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 77. SOUTH KOREA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 78. SOUTH KOREA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 79. REST OF ASIA-PACIFIC RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 80. REST OF ASIA-PACIFIC RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 81. REST OF ASIA-PACIFIC RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 82. LAMEA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 83. LAMEA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 84. LAMEA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 85. LAMEA HOSPITALS RECOMBINANT VACCINES MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 86. LAMEA RECOMBINANT VACCINES MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 87. BRAZIL RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 88. BRAZIL RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 89. BRAZIL RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 90. SAUDI ARABIA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 91. SAUDI ARABIA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 92. SAUDI ARABIA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 93. SOUTH AFRICA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 94. SOUTH AFRICA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 95. SOUTH AFRICA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 96. REST OF LAMEA RECOMBINANT VACCINES MARKET, BY INDICATION, 2021-2031 ($MILLION)

TABLE 97. REST OF LAMEA RECOMBINANT VACCINES MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 98. REST OF LAMEA RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 99.PFIZER INC.: COMPANY SNAPSHOT

TABLE 100.PFIZER INC.: OPERATING SEGMENTS

TABLE 101.PFIZER INC.: PRODUCT PORTFOLIO

TABLE 102.PFIZER INC.: NET SALES,

TABLE 103.PFIZER INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.RECOMBINANT VACCINES MARKET SEGMENTATION

FIGURE 2.RECOMBINANT VACCINES MARKET,2021-2031

FIGURE 3.RECOMBINANT VACCINES MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.RECOMBINANT VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.RECOMBINANT VACCINES MARKET,BY INDICATION,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINES MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MENINGOCOCCAL RECOMBINANT VACCINES MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS RECOMBINANT VACCINES MARKET,2021-2031(%)

FIGURE 16.RECOMBINANT VACCINES MARKET,BY END USER,2021(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PEDIATRIC RECOMBINANT VACCINES MARKET,2021-2031(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ADULTS RECOMBINANT VACCINES MARKET,2021-2031(%)

FIGURE 19.RECOMBINANT VACCINES MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITALS RECOMBINANT VACCINES MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF VACCINATION CENTERS RECOMBINANT VACCINES MARKET,2021-2031(%)

FIGURE 22.RECOMBINANT VACCINES MARKET BY REGION,2021

FIGURE 23.U.S. RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 24.CANADA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 25.MEXICO RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 26.GERMANY RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 27.FRANCE RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 28.UK RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 29.ITALY RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 30.SPAIN RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 31.REST OF EUROPE RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 32.JAPAN RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 33.CHINA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 34.AUSTRALIA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 35.INDIA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 36.SOUTH KOREA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 37.REST OF ASIA-PACIFIC RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 38.BRAZIL RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 39.SAUDI ARABIA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 40.SOUTH AFRICA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 41.REST OF LAMEA RECOMBINANT VACCINES MARKET,2021-2031($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46.COMPETITIVE DASHBOARD

FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 48.PFIZER INC..: NET SALES ,($MILLION